March 11, 2022

Multiple Sclerosis and Cannabis Use: Where Do Patients Get Their Information?

Survey suggests need for evidence-based education among patients and providers alike

22-NEU-2672858_medical-cannabis_650x450

Many people with multiple sclerosis (MS) use cannabis, yet few rely on their MS physicians for information about it, according to a nationwide survey led by Cleveland Clinic researchers. Nearly half the survey respondents said their primary source of medical guidance about the drug was themselves —or nobody.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Patients with MS may not think to turn to their physicians for information about cannabis because it’s not a prescription drug,” says the study’s senior author, Robert Fox, MD, staff neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research. “Physicians, in turn, generally aren’t knowledgeable about specific cannabis products or data regarding efficacy, safety, dosing and patient selection.”

Essentials of the survey design and respondents

The study report, published online in Neurology: Clinical Practice, details findings of a survey of patients with MS about ∆9-tetrahydrocannabinol-containing cannabis. The survey, conducted in March-April 2020, was administered by invitation to active U.S. participants (N = 6,934) in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.

Overall, 3,249 participants (47%) responded. Respondents were predominantly female (78.5%) and white (88.5%), and 62.5% were taking disease-modifying therapy for their MS. The respondent cohort had a mean age of 61.3 years, mean age at MS symptom onset of 31.2 years and median disability level of 3-Gait Disability.

Thirty-one percent of respondents reported ever having used cannabis to treat MS symptoms; of these, 20% currently used it.

Among respondents overall, 76.1% lived in a state where cannabis was currently legal. Cannabis ever-users were more likely than never-users to live in such a state (81.5% vs. 73.7%; P < 0.0001).

Advertisement

Top-line findings

The survey was designed to explore registry participants’ sources of information about cannabis for MS, their perceptions of dialogue with healthcare providers about cannabis use, and their sources of cannabis products and information on their contents.

Among cannabis ever-users, the users themselves or “nobody” was most often cited as the primary source of medical guidance about the drug (48% of responses), followed by a cannabis dispensary professional (21%). Only 12% of users primarily relied on their MS physician, although 70% had discussed cannabis with that medical professional, and an additional 13% cited another physician, a pharmacist or another healthcare provider.

More than half of overall survey respondents (56%) said they would be very comfortable discussing cannabis use for symptom management with their MS physician. When asked if they thought their MS physician would be comfortable if they used cannabis for MS, 34% of current nonusers and 22% of current users said no.

“It’s concerning that a substantial minority of MS patients are unlikely to seek guidance about cannabis from their physician,” says Dr. Fox. “This seems to be linked to a sense that the physician would be uncomfortable with their patients’ use of the drug. That was largely the case among respondents in states where cannabis was not legal currently.”

Among current users of cannabis, 62% typically obtained it from a dispensary, with most others getting it from a family member or friend (18%) or from an acquaintance (13%). Dispensaries were the most common source of information on cannabis contents (39%), followed by word of mouth/dealer/friend (29%) and unregulated product labels (24%). Perceived quality and safety was the leading factor driving choice of cannabis product among current users, cited by 70%, followed by access to preferred THC and/or CBD potencies/formulations (40%), location (39%) and sales support (31%).

Advertisement

Implications for practice

“The possibility of pharmacologic interactions with cannabis is high because CBD and THC affect common targets for drug metabolism,” says Dr. Fox. “Additionally, cannabis can have unintended side effects. This is why it’s important that physicians know about their patients’ use of cannabis for MS and that patients feel comfortable talking about it with their MS physician.”

The main practical implications of the survey findings, according to Dr. Fox, are twofold: evidence-based education around cannabis is needed for physicians and patients with MS, and physicians need to take a more active role in providing medical guidance about cannabis.

Related Articles

photo of doctor performing neurologic exam on a patient
August 11, 2023
A New Guide to the Differential Diagnosis of Multiple Sclerosis

Updated consensus approach helps clinicians efficiently improve diagnostic accuracy

23-NEU-4060108_pregnancy-care-visit_650x450
July 27, 2023
Reproductive Issues and Multiple Sclerosis: 20 Frequently Asked Questions

The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed

23-NEU-3813861 multiple-sclerosis-patient_650x450
July 24, 2023
How the SPRINT-MS Follow-On Study Aims to Enhance Future Trials of Progressive Multiple Sclerosis

In search of optimal imaging biomarkers, best methods for long-term follow-up

23-NEU-3991918 CQD hero_650x450
June 26, 2023
For Older Patients With Multiple Sclerosis, Discontinuing Disease-Modifying Therapy May Be an Option

Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy

23-NEU-3839389-CQD-Hero-650&#215;450
May 24, 2023
DELIVER-MS Trial Extended to Guide Philosophy for Long-Term Multiple Sclerosis Therapy

$1.1M award expands follow-up to six years with focus on clinical endpoints

23-NEU-3839387-stiff-curved-back-650&#215;450
May 12, 2023
Unique Database Yields Insights Into Familial Clustering in Stiff-Person Spectrum Disorder

Mounting evidence of possible shared genetic predisposition

brain MRI showing central vein sign in a patient with multiple sclerosis
May 5, 2023
The Case for Including the Central Vein Sign in the Next Diagnostic Criteria for Multiple Sclerosis

Biomarker promises a practical way to reduce misdiagnoses

intravenous infusion line
April 26, 2023
Shorter Ocrelizumab Infusion Time for Multiple Sclerosis Does Not Affect Safety Profile

No notable difference in reactions with two-hour infusion in ENSEMBLE PLUS substudy

Ad